RESCRIPTOR Drug Patent Profile
✉ Email this page to a colleague
When do Rescriptor patents expire, and what generic alternatives are available?
Rescriptor is a drug marketed by Viiv Hlthcare and is included in one NDA.
The generic ingredient in RESCRIPTOR is delavirdine mesylate. Additional details are available on the delavirdine mesylate profile page.
Summary for RESCRIPTOR
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 73 |
Clinical Trials: | 7 |
Patent Applications: | 4,327 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for RESCRIPTOR |
DailyMed Link: | RESCRIPTOR at DailyMed |
Recent Clinical Trials for RESCRIPTOR
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Institutes of Health (NIH) | Phase 2/Phase 3 |
National Institute of Mental Health (NIMH) | Phase 2/Phase 3 |
University of California, San Diego | Phase 2/Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for RESCRIPTOR
US Patents and Regulatory Information for RESCRIPTOR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Viiv Hlthcare | RESCRIPTOR | delavirdine mesylate | TABLET;ORAL | 020705-001 | Apr 4, 1997 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Viiv Hlthcare | RESCRIPTOR | delavirdine mesylate | TABLET;ORAL | 020705-002 | Jul 14, 1999 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for RESCRIPTOR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Viiv Hlthcare | RESCRIPTOR | delavirdine mesylate | TABLET;ORAL | 020705-001 | Apr 4, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
Viiv Hlthcare | RESCRIPTOR | delavirdine mesylate | TABLET;ORAL | 020705-001 | Apr 4, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
Viiv Hlthcare | RESCRIPTOR | delavirdine mesylate | TABLET;ORAL | 020705-002 | Jul 14, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for RESCRIPTOR
See the table below for patents covering RESCRIPTOR around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Canada | 2328703 | FORMULATION DE DELAVIRDINE EN COMPRIME (DELAVIRDINE TABLET FORMULATION) | ⤷ Try a Trial |
Australia | 4213499 | ⤷ Try a Trial | |
Slovenia | 1083885 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |